HER2+ advanced breast cancer: trastuzumab emtansine best for patients unsuitable for taxane therapy

  • Perez EA & al.
  • Cancer
  • 18 Jul 2019

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The final phase 3 results from MARIANNE show that trastuzumab emtansine (T-DM1) with or without pertuzumab has similar OS compared with trastuzumab with taxane among patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (aBCa).
  • T-DM1 without pertuzumab (T-DM1+placebo) displayed greater tolerability.

Why this matters

  • Previous results showed similar PFS across groups and greater tolerability of T-DM1+placebo.
  • Authors conclude that T-DM1 is a first-line treatment for patients with metastatic HER2+ BCa who are considered unsuitable for taxane-based therapy.

Study design

  • 1095 women in 38 countries were randomly assigned to T-DM1+placebo, T-DM1+pertuzumab, or taxane+trastuzumab (control group).
  • OS was the primary outcome.
  • Funding: F. Hoffmann-La Roche, Ltd.

Key results

  • Median follow-up was approximately 54 months.
  • Median OS was no different across groups (T-DM1+placebo, 53.7 months; T-DM1+pertuzumab, 51.8 months; and control group, 50.9 months). Compared with control, T-DM1+placebo had stratified HR, 0.93; 97.5% CI, 0.73-1.20 and T-DM1+pertuzumab had stratified HR, 0.86; 97.5% CI, 0.67-1.11.
  • The median time to clinically meaningful deterioration in neurotoxicity symptoms was shorter in the control group (2.1 months) and T-DM1+pertuzumab group (4.2 months) than the T-DM1+placebo group (6.2 months).
  • The T-DM1+placebo group had lower rates of alopecia, diarrhea, and fewer treatment-related adverse events.

Limitations

  • None were reported by the authors.

 

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit